Multiple Myeloma

Filter By:
24:17
Filmed at the 2014 Great Debates and Updates in Hematologic Malignancies Congress in New York, this online activity is comprised of three videos wherein Dr. James M. Epstein is joined by Drs. Robert Z. Orlowski, David P. Steensma, and John P. Leonard to discuss recent clinical advances in hematologic malignancies. This engaging conversational forma...
by:imedex | 94 views
08:22
Dr Kenneth Anderson (Dana Farber Cancer Institute, Boston, USA) chairs a discussion with Prof Gareth Morgan (The Royal Marsden Hospital, London, UK) and Prof Paul Richardson (Harvard Medical School, Boston, USA) at Myeloma 2014 about the treatment of myeloma. They discuss the trends in therapy the...
by:Myeloma2014 | 633 views
12:25
Dr Anderson (Dana Farber Cancer Institute, Boston, USA) chairs a discussion with Prof Palumbo (University of Torina, Torina, Italy), Prof Gareth Morgan (The Royal Marsden Hospital, London, UK), and Prof San Miguel (University Hospital, Salamanca, Spain) at Myeloma 2014 about the treatment of Myeloma...
by:Myeloma2014 | 486 views
16:14
Prof Keith Stewart (Mayo Clinic, Scottsdale, USA) chairs a discussion with Prof Gareth Morgan (The Royal Marsden Hospital, London, UK), Dr Leif L. Bergsagel (Mayo Clinic, Scottsdale, Arizona), and Prof Antonio Palumbo (University of Torina, Torina, Italy) at Myeloma 2014, about the treatment of myel...
by:Myeloma2014 | 404 views
03:38
Dr Ola Landgren from Memorial Sloan Kettering, New York, USA, tells the European Medical Journal about the possible enormous value of minimal residual disease (MRD) monitoring in multiple myeloma (MM) as a potential new end-point in MM clinical trials, and as a marker of therapeutic response.
by:PatientPowerEU | 649 views
03:08
Dr Ola Landgren from Memorial Sloan Kettering, New York, USA, summarises the promise with the plethora of new agents in multiple myeloma (MM). He mentions the PANORAMA study, spindle kinase inhibitors and monoclonal antibodies, such as the CD38 class. Dr Landgren comments on the two CD38-specific monoclonal antibodies, daratumumab and SAR650984, ...
by:PatientPowerEU | 631 views
02:54
Dr Ola Landgren from Memorial Sloan Kettering, New York, USA, summarises recent plethora of data in patients with newly diagnosed myeloma. A key recent advance is to treat patients more aggressively earlier with three drug combinations. He outlines latest views on MRD (minimal residual disease), and highlights the promising findings in older pati...
by:PatientPowerEU | 597 views
03:18
Dr Ola Landgren from Memorial Sloan Kettering, New York, USA, speaks to the European Medical Journal from the 19th Congress of the European Haematology Association (EHA) meeting about the changed definition of multiple myeloma. A result of a 2-day workshop of the international myeloma working group before the EHA meeting, the definition now inclu...
by:PatientPowerEU | 511 views
03:39
Dr Ola Landgren from Memorial Sloan Kettering, New York, USA, tells the European Medical Journal about the possible enormous value of minimal residual disease (MRD) monitoring in multiple myeloma (MM) as a potential new end-point in MM clinical trials, and as a marker of therapeutic response.
by:EMJ | 452 views
03:10
Dr Ola Landgren from Memorial Sloan Kettering, New York, USA, summarises recent plethora of data in patients with newly diagnosed myeloma. A key recent advance is to treat patients more aggressively earlier with three drug combinations. He outlines latest views on MRD (minimal residual disease), and highlights the promising findings in older pati...
by:EMJ | 407 views

Top Tags



Please help us provide the best service.
I'm intersted in oncology videos because I'm a...

Oncologist 
Different type of MD 
Nurse 
Other oncology Professional 
Patient/Advocate 
Something Else 

No Thanks(close window)
Membership has its privileges.
 I want the OncologyTube newsletter 

 I want to share videos & receive the newsletter 

I already have an account log me in.


username:   password: remember me

Sign In

Username:
Password:
Remember me
Forgot your password?
Not Yet a Member? Sign up for FREE here!
(Skip Ad)